Find Out if You Qualify for a Financial Reward by filling out the form below.
Investigation Details
Biomea issued a press release on June 6, 2024, announcing that it “has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea’s ongoing Phase I/II clinical trials of the Company’s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.”
Following this news, shares of Biomea fell over 59% in after hours trading on the same day.
Ticker Symbol | Company Name | Join Deadline | Join |
---|---|---|---|
APLT | Applied Therapeutics, Inc. | February 18, 2025 | Join |
BIOA | BioAge Labs, Inc. | March 10, 2025 | Join |
PCRX | Pacira BioSciences, Inc. | March 14, 2025 | Join |
NVO | Novo Nordisk A/S | March 25, 2025 | Join |
GO | Grocery Outlet Holding Corp. | March 31, 2025 | Join |
NEM | Newmont Corporation | April 01, 2025 | Join |
GSK | GSK plc | April 07, 2025 | Join |
NTLA | Intellia Therapeutics, Inc. | April 14, 2025 | Join |
MRK | Merck & Co., Inc. | April 14, 2025 | Join |